+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Trends in overall survival and costs of multiple myeloma, 2000–2014


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Little real-world evidence is available to describe the recent trends in treatment costs and outcomes for patients with multiple myeloma (MM). Using the Truven Health MarketScan Research Databases linked with social security administration death records, this study found that the percentage of MM patients using novel therapy continuously increased from 8.7% in 2000 to 61.3% in 2014. Compared with MM patients diagnosed in earlier years, those diagnosed after 2010 had higher rates of novel therapy use and better survival outcomes; patients diagnosed in 2012 were 1.25 times more likely to survive 2 years than those diagnosed in 2006. MM patients showed improved survival over the study period, with the 2-year survival gap between MM patients and matched controls decreasing at a rate of 3% per year. Total costs among MM patients have increased in all healthcare services over the years; however, the relative contribution of drug costs has remained fairly stable since 2009 despite new novel therapies coming to market. Findings from this study corroborate clinical data, suggesting a paradigm shift in MM treatment over the past decade that is associated with substantial survival gains. Future studies should focus on the impact on specific novel agents on patients’ outcomes.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: found
          • Article: not found

          Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups.

          Studies of ethnic disparities in malignancies have revealed variation in clinical outcomes. In multiple myeloma (MM), previous literature has focused only on patients of Caucasian and African-American (AA) descent. We present a Surveillance Epidemiology and End Results (SEER)-based outcome analysis of MM patients from a broader range of ethnicities, representing current United States demographics. The SEER 17 Registry data was utilized to analyse adult MM patients diagnosed since 1992 (n = 37,963), as patients of other ethnicities were not well represented prior to that. Overall survival (OS) and myeloma-specific survival (MSS) were compared across different ethnicities stratified by year of diagnosis, registry identification, age, sex and marital-status. Hispanics had the youngest median age at diagnosis (65 years) and Whites had the oldest (71 years) (P < 0·001). Increased age at diagnosis was an independent predictor of decreased OS and MSS. Asians had the best median OS (2·7 years) and MSS (4·1 years), while Hispanics had the worst median OS (2·4 years). These trends were more pronounced in patients ≥ 75 years. Cumulative survival benefit over successive years was largest among Whites (1·3 years) and smallest among Asians (0·5 years). These disparities may be secondary to multifactorial causes that need to be explored and should be considered for optimal triaging of healthcare resources. © 2012 Blackwell Publishing Ltd.
            • Record: found
            • Abstract: not found
            • Article: not found

            Autologous hematopoietic stem-cell transplantation for multiple myeloma.

              • Record: found
              • Abstract: found
              • Article: not found

              Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.

              To describe multiple myeloma (MM) treatment patterns and comorbidities over time in the US.

                Author and article information

                Nature Publishing Group
                September 2017
                23 December 2016
                20 January 2017
                : 31
                : 9
                : 1915-1921
                [1 ]Mayo Clinic , Phoenix, AZ, USA
                [2 ]Celgene Corporation , Summit, NJ, USA
                [3 ]Health Economics and Outcomes Research, Truven Health Analytics Inc., an IBM company , Cambridge, MA, USA
                [4 ]Binghamton University , Binghamton, NY, USA
                [5 ]Dana Farber Cancer Institute , Boston, MA, USA
                Author notes
                [* ]Health Economics and Outcomes Research, Truven Health Analytics Inc., an IBM company , 150 Cambridge Park Drive, Cambridge 02140, MA. E-mail: machaon.bonafede@ 123456truvenhealth.com
                Copyright © 2017 The Author(s)

                This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

                : 09 September 2016
                : 04 November 2016
                : 14 November 2016
                Original Article

                Oncology & Radiotherapy
                Oncology & Radiotherapy


                Comment on this article